WESPAC Advisors SoCal LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

WESPAC Advisors SoCal LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 32.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,105 shares of the company’s stock after selling 21,922 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of WESPAC Advisors SoCal LLC’s holdings, making the stock its 20th biggest position. WESPAC Advisors SoCal LLC’s holdings in Johnson & Johnson were worth $7,135,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of JNJ. Kennedy Capital Management LLC grew its stake in shares of Johnson & Johnson by 18.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock valued at $3,189,000 after purchasing an additional 3,206 shares during the period. Shakespeare Wealth Management Inc. grew its stake in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Shakespeare Wealth Management Inc. now owns 3,467 shares of the company’s stock valued at $540,000 after purchasing an additional 163 shares during the period. Sei Investments Co. grew its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Sei Investments Co. now owns 975,372 shares of the company’s stock valued at $151,914,000 after purchasing an additional 6,097 shares during the period. Rainsberger Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Rainsberger Wealth Advisors Inc. now owns 14,584 shares of the company’s stock valued at $2,271,000 after acquiring an additional 373 shares during the period. Finally, Industrial Alliance Investment Management Inc. grew its stake in shares of Johnson & Johnson by 125.4% during the 3rd quarter. Industrial Alliance Investment Management Inc. now owns 6,671 shares of the company’s stock valued at $1,039,000 after acquiring an additional 3,711 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Morgan Stanley cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Down 0.3 %

Shares of JNJ opened at $146.03 on Wednesday. The stock has a market capitalization of $351.45 billion, a price-to-earnings ratio of 9.10, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The business’s 50 day simple moving average is $148.09 and its 200-day simple moving average is $153.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.40%. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.